Agenus Inc. AGEN
Analyst Ratings
- Consensus
- Buy — 2 Buy · 0 Hold · 0 Sell (2 analysts)
- Avg. Price Target
- $19.50 (+162.4% upside)
Key Stats
- Today's Range
- $7.42 – $8.18
- 50-Day Range
- $2.96 – $8.85
- 52-Week Range
- $2.71 – $8.85
- Volume
- 1.21 million shs
- Average Volume
- 1.36 million shs
- Market Cap
- $334.50 million
- P/E Ratio
- 2.88
- Dividend Yield
- —
Valuation
- P/E Ratio
- 2.88
- Price / Book
- -1.62
- Price / Sales
- 2.52
Short Interest
- Short Interest
- 22.67%
- Days to Cover
- 10.85
Financials (TTM)
- Revenue
- $132.69 million
- Net Income
- $91.94 million
- Net Margin
- 69.29%
- Return on Equity
- -44.66%
- Debt-to-Equity
- -0.15
About Agenus Inc.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
Related Stocks
Compare head-to-head: AGEN vs AMGN·AGEN vs MRNA·AGEN vs HALO·AGEN vs KRYS
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.